6 of an HIV treatment training program (2000-2001) for patients in Casablanca (Morocco),” Sante, vol. 15, no. 2, pp. 73–80, 2005. [20] J. Iguenane, C. Marchand, D. Bodelot, et al., “Implementation of therapeutic education programmes for patients living with HIV in four low-income countries: an evaluative approach,” Sante Publique, vol. 19, no. 4, pp. 323–333, 2007. [21] M. I. B. Nemes, H. B. Carvalho, and M. F. M. Souza, “Antiretroviral therapy adherence in Brazil,” AIDS, vol. 18, supplement 3, pp. S15–S20, 2004. [22] T. R. Glass, S. De Geest, R. Weber, et al., “Correlates of self-reported nonadherence to antiretroviral therapy in HIV- infected patients: the Swiss HIV Cohort Study,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 41, no. 3, pp. 385– 392, 2006. [23] T. P. Giordano, D. Guzman, R. Clark, E. D. Charlebois, and D. R. Bangsberg, “Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale,” HIV Clinical Trials, vol. 5, no. 2, pp. 74–79, 2004. [24] K. R. Amico, W. A. Fisher, D. H. Cornman, et al., “Visual analog scale of ARV adherence: association with 3-day self- report and adherence barriers,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 42, pp. 455–459, 2006. [25] S. Duran, G. Peytavin, P. Carrieri, et al., “The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination,” AIDS, vol. 17, no. 7, pp. 1096–1099, 2003. [26] C. S. Alexander, J. J. Asselin, L. S. L. Ting, et al., “Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease,” Journal of Infectious Diseases, vol. 188, no. 4, pp. 541–548, 2003. [27] M. Duong, L. Piroth, G. Peytavin, et al., “Value of patient self- report and plasma human immunodeﬁciency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response,” Clinical Infectious Diseases, vol. 33, no. 3, pp. 386–392, 2001. [28] J. H. Arnsten, P. A. Demas, H. Farzadegan, et al., “Antiretro- viral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitor- ing,” Clinical Infectious Diseases, vol. 33, no. 8, pp. 1417–1423, 2001. [29] P. W. H. Hugen, N. Langebeek, D. M. Burger, et al., “Assess- ment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (elec- tronic monitoring), patient and nurse report, and therapeutic drug monitoring,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 30, no. 3, pp. 324–334, 2002. [30] F. Romanelli, K. Empey, and C. Pomeroy, “Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection,” AIDS Patient Care and STDs, vol. 16, no. 9, pp. 405–411, 2002. [31] F. Rouet, D. K. Ekouevi, M.-L. Chaix, et al., “Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeﬁciency virus type 1 infection in a West African resource-limited setting,” Journal of Clinical Microbi- ology, vol. 43, no. 6, pp. 2709–2717, 2005. [32] L. Ferradini, D. Laureillard, N. Prak, et al., “Positive outcomes of HAART at 24 months in HIV-infected patients in Cambo- dia,” AIDS, vol. 21, no. 17, pp. 2293–2301, 2007. [33] B. Spire, P. Carrieri, P. Sopha, et al., “Adherence to antiretro- viral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment,” Antiviral Therapy, vol. 13, no. 5, pp. 697–703, 2008. AIDS Research and Treatment [34] J. H. Oyugi, J. Byakika-Tusiime, K. Ragland, et al., “Treatment interruptions predict resistance in HIV-positive individuals purchasing ﬁxed-dose combination antiretroviral therapy in Kampala, Uganda,” AIDS, vol. 21, no. 8, pp. 965–971, 2007. [35] P. Mee, K. L. Fielding, S. Charalambous, G. J. Churchyard, and A. D. Grant, “Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa,” AIDS, vol. 22, no. 15, pp. 1971–1977, 2008. [36] A. N. Phillips, D. Pillay, A. H. Miners, D. E. Bennett, C. F. Gilks, and J. D. Lundgren, “Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model,” The Lancet, vol. 371, no. 9622, pp. 1443–1451, 2008. [37] H. O. Ramadhani, N. M. Thielman, K. Z. Landman, et al., “Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania,” Clinical Infectious Diseases, vol. 45, no. 11, pp. 1492–1498, 2007.